A clinical briefing on the Acyclovir shortage for providers and prescribers. Covers timeline, availability, prescribing implications, and patient tools.
As a healthcare provider, you've likely seen the downstream effects of Acyclovir supply disruptions firsthand: patients calling for emergency refills, pharmacies unable to fill standing prescriptions, and clinical uncertainty about when — or whether — stock will normalize.
This briefing gives you the clinical and logistical information you need to navigate the current Acyclovir landscape, counsel patients effectively, and ensure continuity of care.
Acyclovir supply issues have evolved over several years:
The injectable form of Acyclovir sodium (50 mg/mL) was the first to be affected. Manufacturing constraints combined with increased demand — partly driven by pandemic-related supply chain disruptions — led to the FDA and ASHP listing Acyclovir injection on their official drug shortage databases.
By late 2024, ASHP reported that Fresenius Kabi's Acyclovir sodium injection (50 mg/mL, 20 mL vial) had returned to full availability. GlaxoSmithKline also increased production of oral tablets, with 400 mg and 800 mg formulations (100-count bottles) back in consistent supply. The 200 mg capsule was the last oral formulation to stabilize.
The situation in 2026 is best described as stable but fragile. Oral Acyclovir is generally available through major distributors. However:
The supply environment has several practical implications for your prescribing decisions:
For outpatient management of HSV and VZV infections, oral Acyclovir remains a first-line option. Key considerations:
For indications requiring parenteral therapy — particularly HSV encephalitis, neonatal herpes, and severe VZV in immunocompromised patients — IV Acyclovir remains the standard of care and has no true equivalent substitute. If IV Acyclovir is unavailable:
If a patient cannot access Acyclovir, the two most appropriate alternatives are:
Both are available as affordable generics. For clinical details, see our patient-facing guide on alternatives to Acyclovir.
Helping patients find Acyclovir (or an alternative) when their pharmacy is out of stock is a growing part of clinical workflows. Here are tools that can help:
Medfinder helps patients and providers locate pharmacies that currently have specific medications in stock. You can direct patients to medfinder.com or integrate pharmacy availability checks into your prescribing workflow.
The ASHP Drug Shortages Resource Center provides real-time updates on Acyclovir injection availability by manufacturer and NDC. This is the most authoritative source for hospital-based supply planning.
The FDA Drug Shortages page tracks current and resolved shortages, including estimated resolution dates when available.
Even when Acyclovir is available, cost can be a barrier for uninsured or underinsured patients. Key pricing data for 2026:
For patients who are uninsured or facing financial hardship:
Direct patients to our guide on saving money on Acyclovir for detailed strategies.
Several trends may affect Acyclovir supply and access in the coming years:
The Acyclovir shortage is a manageable challenge with the right information and tools. As a provider, the most impactful steps you can take are:
For a practical clinical workflow guide, see our companion article on how to help your patients find Acyclovir in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
